B2Core Reveals Its Latest Updates: What’s New?
29.5.2023 17:00:00 EEST | Business Wire | Press release
B2Core, the premier CRM solution trusted by brokers and exchanges around the globe, continues to push the boundaries of innovation with its most recent significant update. This update introduces several advanced features and streamlined operations, giving financial institutions more powerful capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230529005019/en/
Telegram Integration (Graphic: Business Wire)
Let's have a look at the most notable features.
1. Advanced Event Notification Module
A brand-new Event Notification module has been added to the B2Core Back Office, providing admin users with a vast array of customizable event notifications. With the available 27 choices, administrators may send out alerts for various situations, from withdrawal requests to successful registrations.
Notifications are sent out to admin users on time whenever an event occurs, allowing them to respond appropriately. Additionally, the system allows additional admin users to be added to the "Users" category to receive notifications.
For your convenience, the module's event notification channels include email, SMS, Slack, and now Telegram. The "System-Templates" tab is where administrators may adjust settings and select a notification method. All event notifications are simply accessible via the user card, ensuring that vital information is always readily available.
For additional information on the new Event Notifications module, visit the official B2Core documentation page. In addition, there is a detailed How-To Guide and the References page covering more details.
2. Telegram Integration
B2Core now supports integration with Telegram, giving users even more channels to receive alerts. To begin getting Telegram notifications, users first must link their Telegram chat ID profile to their B2Core Back Office account, which is done in the admin's card under "System – Users – Edit user."
Users may configure the appropriate template under the "System – Templates – Telegram" section after navigating to the admin's card. It is now much easier for users to get important notifications on time by adding the Telegram channel to the Event Notifications area.
Step-by-step instructions on creating a Telegram template, activating a Telegram bot, and locating your unique chat ID may be found in our comprehensive How-to articles, ensuring a seamless onboarding process.
3. Detailed cTrader Data
B2Core's cTrader account interface, recently updated, provides an unmatched amount of depth for traders. Equity, Balance, Leverage, Credit, and Free Funds are just a few indications that users may dig into for their current accounts.
In addition, users may examine graphical representations of equity indicators across different timeframes and at different scales to gain a deeper understanding of the data. Access to real-time information on user orders and open positions and extensive historical information on performed trades and other pertinent data is also easily accessible. With this intuitive interface, investors can get all the relevant trading data they need in one convenient location.
4. Simplified Bulk Deposits to Client Accounts
In response to user feedback, the latest update introduces a new feature that simultaneously simplifies the process of depositing funds into multiple accounts. Within the "Accounts" section, the "Update Balances" window allows users to add funds to various designated accounts by uploading a CSV file containing the Email, ID, and precise amount. This streamlined process eliminates manual input, saving time and effort.
Bottom Line
B2Core's latest update cements its position as the CRM solution for brokers and exchanges. Introducing the Event Notification Module, Telegram Integration, Enhanced cTrader Data, and Simplified Bulk Deposits to Client Accounts showcase B2Core's commitment to providing a comprehensive and streamlined platform. Stay tuned for more exciting new features as B2Core continues to drive innovation in the industry!
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230529005019/en/
Contact information
Artyom Goryushin
+44 2080 688 636
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom